Brooklyn ImmunoTherapeutics appoints Jay Sial as Chief Administrative Officer effective July 15, 2021

Ernexa Therapeutics Inc.

Mr. Sial receives $350,000 base salary and annual bonus eligibility up to 35% of base.
Equity grant of 71,000 stock options and 35,700 RSUs, each vesting over four years.
Severance provides 9 months of base salary and COBRA; 12 months if near a change in control.
Previously CFO at Aspen Neurosciences and University of California Irvine Health.
Equity awards are inducement grants approved by compensation committee without stockholder vote.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jay Sial

Chief Administrative Officer

ERNA · Ernexa Therapeutics Inc.

Effective: 2021-07-15
Filed: July 19, 2021, 7:59 PM ET

On July 13, 2021, we announced that Jay Sial, had been appointed as our Chief Administrative Officer, effective July 15, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jay Sial was appointed as Chief Administrative Officer at Ernexa Therapeutics Inc..

Action: appointed
Role: Chief Administrative Officer

Exact text from the filing

On July 13, 2021, we announced that Jay Sial, had been appointed as our Chief Administrative Officer, effective July 15, 2021.

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-21-024792

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.